Physician profile
Fan Yang
NPI 1629340948
$2,422.62
in general payments reported to CMS, 2019-2025
17 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.91 · 2020: $20.00 · 2022: $124 · 2023: $339 · 2024: $637 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $784.90 | 2024-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $377.87 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $277.14 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $244.02 | 2024-2025 | Voquezna |
| Pfizer INC. | $161.38 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $71.84 | 2023 | Farxiga |
| Amarin Pharma, INC. | $66.64 | 2022-2023 | |
| Agepha Pharma Fz LLC | $54.86 | 2024-2025 | Lodoco |
| Esperion Therapeutics, INC. | $53.91 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $44.51 | 2025 | Rexulti |
| Novo Nordisk INC | $41.21 | 2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $38.47 | 2023 | Mounjaro, Jardiance |
| Abbvie INC. | $35.48 | 2023-2024 | Synthroid |
| Insmed, INC. | $31.37 | 2025 | Arikayce |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2023 | Jardiance |
| Gilead Sciences, INC. | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fan Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.